Varma Mutual Pension Insurance Co purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 123,458 shares of the medical research company's stock, valued at approximately $11,168,000.
A number of other hedge funds have also made changes to their positions in EW. BlackRock Inc. bought a new stake in Edwards Lifesciences in the 2nd quarter valued at $5,318,092,000. Norges Bank bought a new position in shares of Edwards Lifesciences during the 4th quarter worth about $803,686,000. Conway Capital Management Inc. bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth about $954,000. TD Asset Management Inc raised its position in shares of Edwards Lifesciences by 6.4% during the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company's stock valued at $66,335,000 after buying an additional 47,051 shares during the last quarter. Finally, Intech Investment Management LLC raised its position in shares of Edwards Lifesciences by 22.2% during the fourth quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company's stock valued at $5,912,000 after buying an additional 12,591 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.
Analyst Ratings Changes
A number of research firms recently weighed in on EW. Leerink Partners raised Edwards Lifesciences from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $87.00 to $101.00 in a research report on Friday, July 24th. Citigroup upped their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Truist Financial raised their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "hold" rating in a research report on Thursday, July 16th. Finally, UBS Group assumed coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price objective on the stock. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $100.27.
Check Out Our Latest Research Report on EW
Insider Transactions at Edwards Lifesciences
In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm's stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 25,570 shares of company stock valued at $2,219,390. Corporate insiders own 0.31% of the company's stock.
Edwards Lifesciences Price Performance
NYSE:EW opened at $89.89 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The company has a 50-day moving average of $89.21 and a 200-day moving average of $84.68. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a market capitalization of $51.76 billion, a price-to-earnings ratio of 51.66, a PEG ratio of 2.25 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. During the same quarter in the previous year, the firm posted $0.67 earnings per share. The firm's revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.
Edwards Lifesciences Profile
(
Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
